Project Grant R43CA295316
Award Date 9/22/25
Completion Date 8/31/27
Dollars Obligated $286K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Diego, CA 92121, USA
Similar Awards
- This Project Grant, awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), aims to develop an integrated workflow that combines computation and experimentation to efficiently expand a metabolomics-based drug discovery dataset. The $350,000 award to Sinopia Biosciences Inc., with a performance period from August 1, 2025 to July 31, 2026, will focus on developing neural network models to enable efficient...
- The National Cancer Institute (NCI) awarded a $881,647 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Panome Bio Inc. in St. Louis, Missouri. The grant supports the company's research into using next-generation metabolomics, the study of small molecule metabolites, to discover novel biomarkers for the early detection and diagnosis of colon cancer. Panome Bio, a for-profit organization, is the first metabolomics contract research organization to offer a...
- This $435,827 Project Grant from the National Cancer Institute (NCI) under the CFDA 93.394 Cancer Detection and Diagnosis Research program supports research conducted by New York University (NYU) School of Medicine to develop deep learning methods for analyzing mass spectrometry imaging (MSI) data. The goal is to make MSI data more accessible to existing machine learning workflows by expanding the dimensionality of the data structure to treat each metabolite or lipid as an individual "color...
- This $2,489,032 federal Project Grant awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports three highly integrated research projects led by investigators at the Sloan-Kettering Institute for Cancer Research in New York. The overarching goal is to determine the roles, regulation, and underlying mechanisms of lipid metabolism in the cancer cell death process known as ferroptosis, and to explore novel cancer therapeutic approaches based on these mechanisms....
- The National Cancer Institute (NCI), through its Cancer Treatment Research program (CFDA 93.395), awarded a $1,233,778 project grant to Matrisome Bio, Inc. of Cambridge, MA. The grant, effective from September 23, 2025 to August 31, 2027, supports the development of an extracellular matrix-targeted theranostic radiopharmaceutical for the treatment of metastatic lung cancer. Matrisome Bio is leveraging its proprietary nanobody technology to create molecularly targeted drugs that can effectively...
- The National Cancer Institute (NCI), part of the National Institutes of Health, has awarded a $398,282 Project Grant to the University of Houston System for the research project "UNRAVELING THE CONNECTION: HOW METABOLISM SHAPES MAMMALIAN PERSISTER SURVIVAL". This grant, funded under the NCI's Cancer Biology Research program (CFDA 93.396), aims to evaluate the role of metabolism in persister cell survival within mammalian cell populations. Persister cells are a small fraction of...
- This $419,133 federal Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) supports the development of the "AscitesPredict" biosensor technology at the Massachusetts Institute of Technology (MIT). The goal is to overcome challenges in predicting therapeutic sensitivities for difficult-to-treat cancers like gastroesophageal and ovarian cancer, by leveraging patient ascites (fluid buildup) as a readily accessible and...
- The National Cancer Institute (NCI) awarded a $730,400 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Sloan-Kettering Institute for Cancer Research in New York. The goal of this 5-year project is to determine how specific metabolic configurations in lung adenocarcinoma (LUAD) cancer cells support the emergence and maintenance of treatment-resistant cell states. The research team will manipulate components of the tricarboxylic acid (TCA) cycle in mouse and...
- This $182,755 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports the development of novel genetic screening technologies to elucidate mechanisms of lineage plasticity in cancer. The principal investigator has expertise in cell biology and genetics, and has made several key technological accomplishments, including: 1) Developing a CRISPR screening platform to identify redundant epigenetic and signaling regulators in cancer, 2) Creating...
- This is a Cooperative Agreement awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), under the Cancer Biology Research federal grant program (CFDA 93.396). The $953,922 award to the Scripps Research Institute in California will fund research to understand the fundamental links between RNA modifications, codon usage, translation, and metabolism in cancer cells. The 5-year project starting on September 1, 2025 aims to identify correlations between...